A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib

BACKGROUND: Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a number of solid tumor including recurrent low-grade serous ovarian carcinoma (LG...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol Res Pract
Hlavní autoři: Takekuma, Munetaka, Wong, Kwong K., Coleman, Robert L.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4880811/
https://ncbi.nlm.nih.gov/pubmed/27231576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40661-016-0026-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky